Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACAT2 | Q9BWD1 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 2/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 2/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17757881 | 0.91 | DRD2 (0.42) | DRD2DRD4KMT2ALMNAMAPK1 | |
| SCHEMBL17757505 | 0.90 | DRD2 (0.41) | ACAT2DRD2DRD4KMT2ALMNA | |
| SCHEMBL17757053 | 0.89 | DRD2 (0.41) | DRD2DRD4KMT2AKDM4ELMNA | |
| SCHEMBL17757743 | 0.83 | MEN1 (0.41) | ACAT2DRD2DRD4KMT2AALDH1A1 | |
| SCHEMBL17757301 | 0.83 | ACAT2 (0.51) | ACAT2DRD2KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL17757741 | 0.81 | ACAT2 (0.49) | ACAT2DRD2PIK3CDPIK3R1HTR2C | |
| SCHEMBL29823199 | 0.81 | ACAT2 (0.53) | ACAT2KMT2ALMNAHTR2CHTR6 | |
| SCHEMBL17757281 | 0.81 | ACAT2 (0.53) | ACAT2KMT2ALMNAHTR2CHTR6 | |
| SCHEMBL16410637 | 0.80 | DRD2 (0.39) | DRD2DRD4KMT2AKDM4EALDH1A1 | |
| SCHEMBL25582707 | 0.78 | ACAT2 (0.32) | ACAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE48992-E1 | Spiroquinoxaline derivatives as inhibitors of non-apoptotic regulated cell-death | HELMHOLTZ ZENTRUM MÜNCHEN-DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) (DE) | 2022-03-29 | — | — | US | disclosed |
| US-10647687-B2 | Spiropyrazine derivatives as inhibitors of non-apoptotic regulated cell-death | HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) (DE) | 2020-05-12 | — | — | US | disclosed |
| US-10280179-B2 | Spiroquinoxaline derivatives as inhibitors of non-apoptotic regulated cell-death | HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) (DE) | 2019-05-07 | — | — | US | disclosed |
| US-20180065982-A1 | SPIROQUINOXALINE DERIVATIVES AS INHIBITORS OF NON-APOPTOTIC REGULATED CELL-DEATH | HELMHOLTZ ZENTRUM MUNCHEN DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) (DE) | 2018-03-08 | — | — | US | disclosed |
| US-9802956-B2 | Spiroquinoxaline derivatives as inhibitors of non-apoptotic regulated cell-death | HELMHOLTZ ZENTRUM MUNCHEN-DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) (DE) | 2017-10-31 | — | — | US | disclosed |
| US-20160222025-A1 | SPIROQUINOXALINE DERIVATIVES AS INHIBITORS OF NON-APOPTOTIC REGULATED CELL-DEATH | HELMHOLTZ ZENTRUM MUNCHEN (DE) | 2016-08-04 | — | — | US | disclosed |
| WO-2016075137-A1 | SPIROPYRAZINE DERIVATIVES AS INHIBITORS OF NON-APOPTOTIC REGULATED CELL-DEATH | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2016-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647687-B2 | Spiropyrazine derivatives as inhibitors of non-apoptotic regulated cell-death | AIFM2, BAD, AIFM1 | ACAT2 1935/4885DRD2 2688/4885DRD4 3450/4885 |
| US-20160222025-A1 | SPIROQUINOXALINE DERIVATIVES AS INHIBITORS OF NON-APOPTOTIC REGULATED CELL-DEATH | AIFM2, BAD, AIFM1 | ACAT2 1509/4885DRD2 3075/4885DRD4 3905/4885 |
| US-10280179-B2 | Spiroquinoxaline derivatives as inhibitors of non-apoptotic regulated cell-death | AIFM2, BAD, AIFM1 | ACAT2 1431/4885DRD2 3073/4885DRD4 3890/4885 |
| US-20180065982-A1 | SPIROQUINOXALINE DERIVATIVES AS INHIBITORS OF NON-APOPTOTIC REGULATED CELL-DEATH | AIFM2, BAD, AIFM1 | ACAT2 1509/4885DRD2 3075/4885DRD4 3905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.